Xolair Proves Effective in Treating AD Symptoms Within Children
Research completed at St. Thomas' NHS Foundation Trust in London has found that Omalizumab (Xolair) can significantly improve symptoms for children with severe atopic dermatitis and enable patients to reduce reliance on topical corticosteroids. While proving clinically effective, the researchers noted that the treatment's cost will play a role in the treatment's use: "Anti-IgE medication may be a cost-effective option in the multisystem, difficult-to-manage allergic disease that burdens many children at the severe end of the spectrum."
Soft Filler Injection Complications Examined in FDA Analysis
Recent research examines the reports of adverse events involving cosmetic injectable soft-tissue fillers from the FDA database from 1993-2014. The researchers identified 3,782 complications, 44% implicated hyaluronic acid fillers, 40% involved poly-L-lactic acid fillers, 15% included calcium hydroxylapatite fillers, and <1% arose from polymethylmethacrylate fillers. The researchers noted that the study "underscores the importance of appropriate skill and training when administering dermal fillers."
Diet and Hidradenitis Suppurativa Link Highlighted in Study Analysis
Research published in the International Journal of Dermatology provides an analysis of 25 previous studies to investigate the relationship between diet and metabolic factors in hidradentis suppurative (HS). Patients with HS were four times more likely to be obese, and while weight loss interventions overall demonstrated improvement, different interventions drew varying results. For instance, after surgical intervention some patients experienced worsening cases of HS, while the exclusion of dairy and yeast drew particularly positive reactions.
Test Your Knowledge
A psoriatic arthritis patient is switched to ustekinumab and while the skin disease improves, joint symptoms worsen. You are concerned about joint disease progression. The next best step for this patient is to increase the dose of ustekinumab.
Meet Dr. Darrell S. Rigel, MD MS-- a current Clinical Professor of Dermatology at NYU Medical Center. Among many prestigious roles, Dr. Rigel has served as President of the American Academy of Dermatology and the American Academy of Dermatology Association. Currently, Dr. Rigel maintains a private practice in Manhattan where he specializes in skin cancer, sun damage, and aging problems of the skin.
New research questions the current rescue approach to AD – aimed at treating flare-ups – and elucidates the potential long-term benefits of newer treatment options, which may both result in elongated remission periods and fewer adverse effects.
